8-K/A: Biofrontera Inc. Secures Full US Rights to Ameluz and RhodoLED, Restructures Relationship with Former Parent

Biofrontera Inc. has entered into a strategic agreement to acquire all U.S. rights to Ameluz and RhodoLED from its former parent, Biofrontera AG, in exchange for royalties, preferred stock, and assumption of significant U.S. market costs and legal liabilities.

Summary

• Biofrontera Inc. (Buyer) is acquiring all U.S. rights to Ameluz (aminolevulinic acid HCl) topical gel, 10%, BF-RhodoLED, and RhodoLED-XL (collectively, the Products) from Biofrontera AG and its subsidiaries (Sellers).
• The transaction aims to modify the existing relationship and facilitate Buyer's financing efforts to continue operations.
• Consideration for the assets includes an agreed royalty, Preferred Stock of Buyer, and the transfer of all U.S. market costs and assumption of defense and costs for certain U.S. legal actions.
• Buyer will bear all costs and risks associated with commercialization and manufacturing of Ameluz and Lamps for the U.S. market.
• A royalty payment structure is effective June 1, 2025: 12% of Ameluz Net Revenues if prior year's annual Net Revenues were less than or equal to $65 million, and 15% if greater than $65 million.
• Buyer must issue Preferred Stock to Sellers convertible into 10% of all outstanding equity of Buyer on a fully diluted, as-converted basis as of the Term Sheet date, including Preferred Stock issued as part of the conditions precedent.
• Buyer must make an upfront payment of EUR 2,593,750 to Sellers by June 30, 2025, covering outstanding invoices and production costs.
• Buyer must provide proof of purchase of $8,500,000 in preferred equity or a third-party loan by June 30, 2025, and an agreement for an additional $2,500,000 by January 1, 2026, or the Transfer Agreement date.
• Buyer assumes full defense and costs for three specific U.S. legal actions: NJ Marketing Litigation, MA Patent Litigation, and ITC Proceeding, effective June 1, 2025.
• Buyer will bear all U.S. Food and Drug Administration (FDA) approval and market authorization costs, including annual fees and clinical trial costs, effective June 1, 2025.
• A minimum annual sales volume of 80,000 tubes of Ameluz is required during the Minimum Royalty Term (until cumulative royalty exceeds $50 million or patent protection expires, whichever is earlier, but no later than May 31, 2031). Failure to meet this or pay minimum royalties (12% of 80,000 tubes) could lead to termination and asset recovery by Sellers.
• Buyer is restricted from issuing additional equity or convertible debt for 12 months post-Preferred Stock issuance (excluding certain types) without Sellers' consent. Sellers also have pari passu participation rights for future equity issuances.
• The existing License and Supply Agreement (LSA) will be terminated or replaced by the Transfer Agreement.

Sentiment

Score: 7

Explanation: The agreement provides Biofrontera Inc. with full control over its key U.S. assets, which is strategically positive for long-term independence and growth. However, it comes with significant financial obligations (upfront payment, capital raise, assumption of all U.S. costs) and substantial legal liabilities, along with a challenging minimum sales volume requirement. The conditions precedent and potential for arbitration add some uncertainty, but the overall intent is to stabilize and enable future operations.

Positives

• Biofrontera Inc. gains full control over U.S. commercialization of Ameluz and RhodoLED, streamlining operations.
• The transaction facilitates Buyer's financing efforts, enabling continued operations.
• Buyer assumes responsibility for significant U.S. legal liabilities, potentially centralizing defense strategy and costs.
• Buyer gains access to clinical trial results from Sellers for non-U.S. development, and Sellers grant an exclusive, fully paid-up U.S. license for their improvements related to certain indications.
• Biofrontera AG, as a significant shareholder, will have board representation rights for three years.

Negatives

• Buyer assumes all costs and risks for U.S. commercialization and manufacturing of Ameluz and Lamps.
• Buyer is obligated to make a substantial upfront payment of EUR 2,593,750 and secure $8,500,000 in preferred equity/debt by June 30, 2025, with an additional $2,500,000 by January 1, 2026.
• Buyer is subject to a minimum annual sales volume of 80,000 Ameluz tubes, with penalties including potential termination of the agreement and asset recovery by Sellers if not met for two consecutive years.
• Buyer assumes significant legal defense costs and potential indemnification for ongoing and future U.S. litigation related to the Products.
• Sellers retain a right of first refusal on asset sales or change of control transactions involving the Assets for five years.
• Buyer is restricted from issuing additional equity for 12 months without Sellers' consent, potentially limiting financing flexibility.

Risks

• Financial Risk: Failure to meet the upfront payment and preferred equity funding conditions by June 30, 2025, will render the Term Sheet null and void.
• Operational Risk: Failure to meet the minimum annual sales volume of 80,000 Ameluz tubes for two consecutive years could lead to termination of the Transfer Agreement and recovery of assets by Sellers.
• Legal Risk: Buyer assumes full responsibility for defense and costs of significant ongoing U.S. legal actions (NJ Marketing Litigation, MA Patent Litigation, ITC Proceeding) and future claims, including indemnification for any judgments or settlements.
• Integration Risk: Transfer of personnel, leases, and operations for regulatory, manufacturing, and pharmacovigilance services needs to be completed smoothly by December 31, 2025.
• Arbitration Risk: If parties cannot agree on necessary assets or Transfer Agreement terms by September 30, 2025, an independent arbitrator will make the determination.
• Funding Risk: The requirement to raise $8.5 million in preferred equity/debt by June 30, 2025, and an additional $2.5 million by January 1, 2026, poses a funding challenge.
• Market Risk: The royalty structure and minimum sales volume are tied to Ameluz net revenues, making Buyer susceptible to market fluctuations and competition.

Future Outlook

Biofrontera Inc. aims to continue its operations by securing full U.S. rights to Ameluz and RhodoLED, facilitating future financing efforts. The company anticipates a formal Transfer Agreement by September 30, 2025, which will finalize the transfer of intellectual property and regulatory authorizations. Buyer will assume all U.S. market costs and legal liabilities, indicating a shift towards greater operational and financial independence for its U.S. business.

Management Comments

• The purpose of this Term Sheet and the final agreement... is to modify the existing relationship between the Parties in order to facilitate the financing efforts of Buyer, enabling it to continue its operations.
• Buyer agrees that its board of directors shall unanimously recommend that the Stockholder Approval be approved by the Buyers stockholders at all meetings at which the Stockholder Approval is considered.

Industry Context

This transaction represents a significant strategic shift for Biofrontera Inc., moving from a licensee/subsidiary relationship to an independent entity fully controlling its key products (Ameluz and RhodoLED) in the crucial U.S. market. This could enhance its competitive position by allowing more direct control over commercialization, pricing, and strategic development within the photodynamic therapy (PDT) and dermatology sectors. The assumption of legal liabilities also centralizes risk management for the U.S. operations.

Comparison to Industry Standards

• The royalty structure (12-15% of net revenues) is within a typical range for pharmaceutical licensing agreements, though specific comparisons would require detailed revenue and cost structures of similar dermatology or PDT product deals.
• The requirement for a minimum annual sales volume (80,000 tubes of Ameluz) is a common feature in licensing or asset transfer agreements to ensure the acquiring party maintains a certain level of commercial effort and revenue generation for the seller.
• The assumption of legal defense costs and indemnification for ongoing litigation is a substantial commitment, often seen in asset carve-out or spin-off transactions where the acquiring entity takes on the operational liabilities associated with the transferred business segment.
• The issuance of preferred stock to the former parent (10% fully diluted) is a common mechanism for the seller to retain an equity interest and participate in the future upside of the divested business, while also providing a non-cash component to the consideration.
• The restriction on future equity issuance for 12 months without the seller's consent, and pari passu participation rights, are protective clauses for the seller's equity stake, common in deals where the seller retains a significant minority interest.

Corporate Governance

Legal Proceedings

• DUSA Pharmaceuticals, Inc., et al., v. Biofrontera Inc., et al.; Civ. No. 3:23-cv-20601-RK-JBD; United States District Court for the District of New Jersey (NJ Marketing Litigation).
• Sun Pharmaceuticals Industries, Inc. v Biofrontera Inc., et al.; Civ. No.: 1:24-CV-11637-IT; United States District Court for the District of Massachusetts (MA Patent Litigation).
• In the Matter of CERTAIN PHOTODYNAMIC THERAPY SYSTEMS, COMPONENTS THEREOF, AND PHARMACEUTICAL PRODUCTS USED IN COMBINATION WITH THE SAME; Investigation No. 337-TA-1411; International Trade Commission (ITC Proceeding).
• Buyer assumes full defense and costs for these actions from June 1, 2025, and indemnifies Sellers for any amounts owed.
• Buyer also agrees to defend and pay Litigation Expenses for any future civil action or demand letter initiated by Sun Pharmaceuticals Industries, Inc. or related entities concerning the marketing, promotion, or sale of the Products in the United States.

Related Party Transactions

• The entire agreement is a related party transaction between Biofrontera Inc. and its former parent company, Biofrontera AG, which also holds approximately 4.23% share ownership in Biofrontera Inc.
• The transaction involves the transfer of U.S. assets (intellectual property, regulatory approvals, inventory, etc.) from the parent group to the subsidiary.
• Consideration includes royalties, preferred stock issuance to the parent, and assumption of costs and legal liabilities by the subsidiary.
• Biofrontera AG retains board appointment rights in Biofrontera Inc. for three years.
• Restrictions on Biofrontera Inc.'s future equity issuances and a right of first refusal for Biofrontera AG on asset sales or change of control transactions.

Stakeholder Impact

• Shareholders (Biofrontera Inc.): Potential dilution from Preferred Stock issuance to Sellers and future capital raises. Increased operational control and potential for long-term value creation from U.S. assets. Assumption of significant legal liabilities could impact profitability.
• Shareholders (Biofrontera AG): Retains an equity stake (10% fully diluted) and royalty stream from U.S. sales, providing continued participation in the U.S. market's success without direct operational burden.
• Employees: Potential transfer of 16 employees and two temporary employees from Sellers to Buyer, with Buyer bearing termination costs if not hired or interested.
• Customers: Expected continued supply of Ameluz and RhodoLED in the U.S. market under Biofrontera Inc.'s direct control.
• Creditors: The capital raise and assumption of liabilities will impact the company's balance sheet and financial risk profile.

Next Steps

• Buyer to make an upfront payment of EUR 2,593,750 by June 30, 2025.
• Buyer to provide proof of $8,500,000 preferred equity purchase or loan by June 30, 2025.
• Parties to negotiate in good faith for consideration regarding clinical trial results access.
• Parties to complete the final transfer of personnel, leases, and associated operations for drug and device regulatory, drug manufacturing, and pharmacovigilance services by December 31, 2025.
• Buyer to secure an agreement for an additional $2,500,000 preferred stock purchase by January 1, 2026, or the Transfer Agreement date.
• Parties to commence procedures to enter into a Transfer Agreement as soon as reasonably practicable after Term Sheet execution, with a target for transfer of IP and regulatory authorizations by September 30, 2025.
• Buyer to file a preliminary proxy statement for stockholder approval of Preferred Stock issuance and schedule a meeting as soon as practicable.
• Buyer to submit stockholder approval for Preferred Stock issuance at least semi-annually until obtained, if not approved at the first meeting.

Key Dates

Recommendation

Keywords

Biofrontera Inc., Biofrontera AG, Ameluz, RhodoLED, Photodynamic Therapy, PDT, SEC Filing, 8-K/A, Asset Acquisition, Intellectual Property, Regulatory Approvals, Pharmaceutical, Medical Device, Royalty Agreement, Preferred Stock, Litigation Assumption, Nasdaq, BFRI, BFRIW